See more : Allied Energy, Inc. (AGGI) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (MDXH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Parker Drilling Company (PKDCW) Income Statement Analysis – Financial Results
- Certive Solutions Inc. (CBP.CN) Income Statement Analysis – Financial Results
- FIRST FINTEC LIMITED (FIRSTFIN.BO) Income Statement Analysis – Financial Results
- Public Joint stock company Rosseti Lenenergo (LSNG.ME) Income Statement Analysis – Financial Results
- Gulf International Services Q.P.S.C. (GISS.QA) Income Statement Analysis – Financial Results
MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.37M | 11.79M | 28.34M | 40.51M | 29.87M | 17.47M | 11.48M | 7.55M | 4.92M | 3.48M | 3.37M | 3.65M | 4.21M | 3.85M | 3.66M | 3.65M | 525.97K |
| Cost of Revenue | 26.26M | 17.84M | 11.83M | 10.52M | 11.93M | 11.65M | 10.20M | 10.10M | 6.91M | 6.45M | 5.79M | 1.19M | 344.76K | 492.09K | 256.46K | 338.28K | 656.10K | 72.59K | 135.02K | 12.20K |
| Gross Profit | 43.93M | 19.22M | 10.41M | 7.85M | -144.00K | 16.69M | 30.31M | 19.76M | 10.56M | 5.03M | 1.76M | 3.72M | 3.14M | 2.88M | 3.39M | 3.87M | 3.19M | 3.58M | 3.51M | 513.77K |
| Gross Profit Ratio | 62.58% | 51.87% | 46.82% | 42.72% | -1.22% | 58.88% | 74.81% | 66.17% | 60.47% | 43.78% | 23.31% | 75.72% | 90.10% | 85.41% | 92.97% | 91.96% | 82.96% | 98.02% | 96.30% | 97.68% |
| Research & Development | 6.38M | 7.56M | 6.67M | 4.54M | 9.00M | 1.81M | 1.83M | -332.00K | 2.10M | 742.00K | 1.58M | 3.29M | 6.23M | 9.06M | 18.75M | 15.31M | 15.60M | 11.41M | 6.85M | 6.23M |
| General & Administrative | 23.01M | 23.54M | 5.07M | 4.15M | 5.68M | 6.19M | 5.35M | 3.95M | 2.97M | 2.50M | 1.86M | 1.80M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Selling & Marketing | 36.92M | 26.58M | 2.59M | 2.31M | 4.43M | 9.07M | 8.15M | 7.61M | 6.02M | 4.91M | 2.50M | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.93M | 50.12M | 7.65M | 6.46M | 10.10M | 15.26M | 13.51M | 11.56M | 8.99M | 7.40M | 4.36M | 4.75M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Other Expenses | 4.96M | -559.00K | 22.93M | 23.97M | 23.92M | 31.71M | 27.25M | 21.39M | 13.85M | 12.22M | 11.90M | 7.46M | -93.32K | -33.25K | 0.00 | 1.39K | -77.27K | -242.84K | -72.25K | -67.78K |
| Operating Expenses | 71.26M | 57.12M | 37.25M | 34.97M | 43.03M | 48.78M | 42.58M | 32.61M | 24.94M | 20.37M | 17.83M | 15.50M | 12.34M | 14.01M | 24.50M | 19.64M | 19.25M | 14.18M | 8.72M | 7.70M |
| Cost & Expenses | 97.52M | 74.95M | 49.08M | 45.50M | 54.95M | 60.44M | 52.78M | 42.71M | 31.85M | 26.82M | 23.63M | 16.70M | 12.68M | 14.50M | 24.76M | 19.98M | 19.91M | 14.25M | 8.86M | 7.71M |
| Interest Income | 1.09M | 125.00K | 11.00K | 4.00K | 10.00K | 21.00K | 0.00 | 6.00K | 13.00K | 14.00K | 16.00K | 87.29K | 277.36K | 295.25K | 644.74K | 1.59M | 1.53M | 868.43K | 138.57K | 146.40K |
| Interest Expense | 5.58M | 6.14M | 1.88M | 1.35M | 318.00K | 82.00K | 0.00 | 0.00 | 99.00K | 23.00K | 20.00K | 357.08K | 82.95K | 113.05K | 28.65K | 12.53K | 1.61M | 1.11M | 210.82K | 214.19K |
| Depreciation & Amortization | 6.86M | 4.91M | 3.04M | 3.33M | 3.42M | 2.94M | 2.21M | 1.72M | 881.00K | 333.00K | 418.00K | 527.68K | 397.90K | 462.83K | 3.29M | 1.40M | 839.81K | 497.56K | 280.70K | 325.34K |
| EBITDA | -30.47M | -36.39M | -23.99M | -23.79M | -39.74M | -29.47M | -10.19M | -11.57M | -13.50M | -14.88M | -15.59M | -9.80M | -9.22M | -10.37M | -16.66M | -13.43M | -12.86M | -8.77M | -4.93M | -6.86M |
| EBITDA Ratio | -43.41% | -89.03% | -107.46% | -130.55% | -338.88% | -104.00% | -24.88% | -37.25% | -77.29% | -130.33% | -203.20% | -228.77% | -244.73% | -307.41% | -470.29% | -303.54% | -395.27% | -276.04% | -135.09% | -1,304.64% |
| Operating Income | -27.33M | -37.90M | -26.84M | -27.12M | -43.17M | -32.10M | -12.27M | -12.85M | -14.38M | -15.34M | -16.07M | -11.78M | -9.20M | -11.13M | -21.11M | -15.77M | -16.00M | -10.35M | -5.14M | -7.12M |
| Operating Income Ratio | -38.93% | -102.28% | -120.69% | -147.63% | -366.30% | -113.27% | -30.30% | -43.01% | -82.34% | -133.65% | -212.75% | -239.50% | -264.12% | -329.89% | -578.14% | -374.54% | -415.41% | -283.00% | -140.80% | -1,353.61% |
| Total Other Income/Expenses | -15.77M | -6.14M | -2.16M | -1.54M | -506.00K | -393.00K | -127.00K | -441.00K | -91.00K | 86.00K | -104.00K | -89.00K | 209.00K | 182.21K | 616.08K | 853.66K | 1.45M | 625.59K | -180.88K | 78.62K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -32.49M | -12.40M | -13.29M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.94M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -156.01% | -370.60% | -114.66% | -30.61% | -44.49% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -324.49% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| Income Tax Expense | 1.00K | 6.14M | 1.88M | 1.35M | -575.00K | -41.00K | -113.00K | -113.00K | 86.00K | 9.00K | 4.00K | 91.25K | -194.41K | 31.92K | -616.08K | -1.58M | -1.61M | -1.11M | -210.82K | -214.19K |
| Net Income | -43.10M | -50.19M | -30.88M | -30.01M | -43.10M | -32.45M | -12.29M | -13.17M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.98M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Net Income Ratio | -61.40% | -135.45% | -138.84% | -163.33% | -365.72% | -114.51% | -30.33% | -44.11% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -325.43% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| EPS | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| EPS Diluted | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
MDxHealth to Present First Quarter 2023 Financial Results on May 15
NEWS RELEASE 1 MAY 202 3 , 4PM ET / 22 :00 CET
MDxHealth SA (MXDHF) Q4 2022 Earnings Call Transcript
MDxHealth SA (OTCPK:MXDHF) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Francois Brisebois - Oppenheimer Mark Massaro - BTIG Thomas Franken - KBC Securities...
Why Is MDxHealth (MDXH) Stock Down 40% Today?
MDxHealth (NASDAQ: MDXH ) stock is falling on Friday after the healthcare company revealed plans for a proposed public stock offering. With this offering, MDxHealth is seeking to sell $40 million of its American Depositary Shares (ADSs) through the Nasdaq...
MDxHealth SA (MXDHF) CEO Michael McGarrity on Q4 2021 Results - Earnings Call Transcript
MDxHealth SA (MXDHF) CEO Michael McGarrity on Q4 2021 Results - Earnings Call Transcript
MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NEWS RELEASE 9 FEBRUARY 2022, 4:00 PM EST / 22:00 CET
Source: https://incomestatements.info
Category: Stock Reports